EVALUATION OF THE JAK2V617F MUTATIONAL BURDEN
IN PATIENTS WITH PHILADELPHIA CHROMOSOME
NEGATIVE MYELOPROLIFERATIVE NEOPLASMS:
A SINGLE-CENTER EXPERIENCE
Popova-Labachevska M1, Panovska-Stavridis I1,*, Eftimov A2, Kapedanovska Nestorovska A2,
Cevreska L1, Ivanovski M1, Ridova N1, Trajkova S1, Dimovski AJ2,*
*Corresponding Author: Associate Professor Irina Panovska-Stavridis, M.D., Ph.D., University Clinic
of Hematology, UKIM-Faculty of Medicine, University Cyril and Methodious,” Majka Tereza 47, Skopje,
RN Macedonia. Tel/Fax: +38923111749. E-mail: ukhematologija@t.mk and/or Professor Aleksandar J.
Dimovski, M.D., Ph.D., Center for Biomolecular Pharmaceutical Analyses, UKIM-Faculty of Pharmacy,
University “Ss Cyril and Methodius,” Majka Tereza 47, Skopje, RN Macedonia. Tel/Fax: +38923119694.
E-mail: adimovski@ff.ukim.edu.mk
page: 31
|
|
REFERENCES
1. Barbui T, Thiele J, Gisslinger H, Kvasnicka HM,
Vannucchi AM, Guglielmelli P, et al. The 2016 WHO
classification and diagnostic criteria for myeloproliferative
neoplasms: document summary and in-depth
discussion. Blood Cancer J. 2018; 8(2): 15-25.
2. Vannucchi AM, Harrison CN. Emerging treatment
for classical myeloproliferative neoplasms. Blood.
2017; 129(6): 693-703.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt
R, Passweg JR, et al. A gain-of-function mutation of
JAK2 in myeloproliferative disorders. N Engl J Med.
2005; 352(17): 1779-1790.
4. Singdong R, Siriboonpiputtana T, Chareonsiri-suthigul
T, Kongruang A, Limsuwanachot N, Sirirat T, et al.
Characterisation and prognosis significance of JAK2
(V617F), MPL and CALR mutations in Philadelphia
negative myeloproliferative neoplasms. Asian Pac J
Cancer Prev. 2016; 17(10): 4647-4653.
5. Alshemmari SH, Rajaan R, Ameen R, Al-Drees MA,
Almosailleakh MR. JAK2V617F allele burden in
patients with myeloproliferative neoplasms. Ann Hematol.
2014; 93(5): 791-796.
6. Perricone M, Polverelli N, Martinelli G, Catani L,
Ottaviani E, Zuffa E, et al. The relevance of a low
JAK2 V617F allele burden in clinical practice: A
monocentric study. Oncotarget. 2017; 8(23): 37239-
37249.
7. Ha, JS, Kim YK, Jung SI, Jung HR, Chung, IS. Correlations
between Janus Kinase 2V617F allele burdens
and clinicohematologic parameters in myeloproliferative
neoplasms. Ann Lab Med. 2012; 32(6): 385-391.
8. Jovanovic JV, Ivey A, Vannucchi AM, Lippert E,
Oppliger Leibundgut E, et al. Establishing optimal
quantitative-polymerase chain reaction assays for
routine diagnosis and tracking of minimal residual
disease in JAK2-V617F-associated myeloproliferative
neoplasms: A joint European LeukemiaNet
MPN&MPNr-EuroNet (COST action BM0902)
study. Leukemia. 2013; 27(10): 2032-2039. 9. Malysz J, Crisan D. Correlation of JAK2 V617F mutant
allele quantification with clinical presentation
and type of chronic myeloproliferative neoplasm.
Ann Clin Lab Sci. 2009; 39(4): 345-350.
10. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi
A, Longo G, et al. Influence of JAK2V617F
allele burden on phenotype in essential thrombocythemia.
Haematologica. 2008; 93(1): 41-48.
11. Silver RT, Vandris K, Wang YL, Adriano F, Jones AV,
Christos PJ, et al. JAK2V617F allele burden in polycythemia
vera correlates with grade of myelofibrosis,
but is not substantially affected by therapy. Leukemia
Res. 2011; 35(2): 177-182.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
